15 jun: Salg af egne aktier til direktion og medarbejdere samt tildeling ..
15 jun: Nordea Bank AB (publ): Forøgelse af antal udestående certifikater..
15-06-2018 13:32:13

Grant of Warrants

Relateret indhold
Relateret debat
13 jul - 
Njaaah, okay så 😊
13 jul - 
Det er  jo faktisk også det jeg skriver
13 jul - 
hofpeung - jeg forstår din tilgang, men tingene k..

June 15, 2018

Announcement no. 11

In accordance with the company's guidelines relating to incentive remuneration and the authorization in Section 18 of the Articles of Association, the Board of Directors of BioPorto A/S ("BioPorto") (Nasdaq: BIOPOR) has decided to issue 900,000 new warrants to BioPorto’s Chief Financial Officer, Ole Larsen, in connection with his employment in BioPorto A/S.

The issuance of new warrants will support the company's long-term goals and establish a performance-based remuneration reflecting the company's and shareholders' interests.

Each warrant grants the holder the right to subscribe for one share in the company. The exercise price is fixed at DKK 3.11 per share. Warrants will be exercisable from June 15, 2020 – June 14, 2023. Within the exercise period, warrants can be exercised within ordinary trading windows.

Conditions for cancellation of all warrants apply in case the Company does not achieve FDA approval of The NGAL Test™. The program also includes conditions on claw-back in case of erroneous financial information and on accelerated vesting in case of e.g. takeover bid, resolution and business transfer.

Detailed terms of the warrants are to be found in the Articles of Association on www.bioporto.com under Investor Relations> Governance> Company Articles.

The total number of shares that the holder of warrants will be able to subscribe upon exercise of the warrants, are 900,000. The theoretical market value of the allocations of warrants amounts to DKK 575,475. The calculation is based on the Black-Scholes formula using an interest rate of -0.556% and the historical volatility of BioPorto A/S' shares of 24 months calculated to 37.6%.

For further information, please contact:

Thomas Magnussen, Chairman of the Board

Gry Husby Larsen, General Counsel

Telephone +45 4529 0000, e-mail investor@bioporto.com

About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.

Attachment

Primary Logo

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
13 jul
BIOPOR
Man kan diskuterer frem og tilbage om Bioporto får godkendt NgAL, men de fleste er nok enige i at de..
1
12 jul
BIOPOR
Så er der under 20 dage (10 børsdage) tilbage til de skal indsende deres FDA bliver spændende og se ..
1

Fondsbørsmeddelelser

#

EuroInvestor: I fokus
#

#

EuroInvestor: I fokus
#

#

EuroInvestor: I fokus
#

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas/UBS: Indleder med købsanbefaling og ser aktien stige 37 pct.
2
Novo/ABM: Recepttal understøtter forventning om opjustering
3
Genmab/Jefferies: Darzalex øger tilliden til ledelsens forventninger
4
Aktier/tendens: Genmab og kolleger får udlandsnyt i let nervøs åbning
5
Aktier/åbning: Vestas fører an i positivt C25-indeks

Relaterede aktiekurser

BioPorto A/S 3,150 0,5% Stigning i aktiekurs
Bioporto Ord Shs 3,095 -1,3% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Seneste nyheder


Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
18. juli 2018 02:51:09
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180712.1 - EUROWEB3 - 2018-07-18 02:51:09 - 2018-07-18 02:51:09 - 1 - Website: OKAY